Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres

被引：2

作者：

Poirel, Helene A. ^{[1
]}

Vanspauwen, Marijke ^{[1
]}

Macq, Gilles ^{[1
]}

De Geyndt, Anke ^{[1
]}

Maertens, Johan ^{[2
]}

Willems, Evelyne ^{[3
]}

Selleslag, Dominik ^{[4
]}

Poire, Xavier ^{[5
]}

Theunissen, Koen ^{[6
]}

Graux, Carlos ^{[7
]}

Kerre, Tessa ^{[8
,9
]}

Zachee, Pierre ^{[10
,11
]}

Meuleman, Nathalie ^{[12
]}

De Becker, Ann ^{[13
]}

Verlinden, Anke ^{[14
]}

Van Obbergh, Florence ^{[15
]}

Schuermans, Christine ^{[16
]}

De Wilde, Virginie ^{[17
]}

Jaspers, Aurelie ^{[18
]}

Pranger, Delphine ^{[19
]}

Deeren, Dries ^{[20
]}

Van Riet, Ivan ^{[13
,21
]}

Vaes, Evelien ^{[1
]}

Beguin, Yves ^{[3
,9
,11
,18
]}

机构：

[1] Belgian Canc Registry, Brussels, Belgium

[2] UZ Gasthuisberg Leuven, Leuven, Belgium

[3] CHU Liege, Liege, Belgium

[4] AZ Sint Jan Brugge Oostende, Brugge, Belgium

[5] UCL St Luc, Brussels, Belgium

[6] Jessa Ziekenhuis, Hasselt, Belgium

[7] CHU UCL Namur Godinne site, Yvoir, Belgium

[8] UZ Gent, Ghent, Belgium

[9] Belgian Hematol Soc Transplant Comm, Brussels, Belgium

[10] ZNA Antwerpen, Antwerp, Belgium

[11] Belgian Transplant Registry, Brussels, Belgium

[12] Inst Jules Bordet, Brussels, Belgium

[13] UZ Brussel, Brussels, Belgium

[14] Univ Antwerp Hosp, Edegem, Belgium

[15] Hop Jolimont, La Louviere, Belgium

[16] GZA Sint Augustinus, Antwerp, Belgium

[17] Erasmus Brussel, Brussels, Belgium

[18] CHR Citadelle, Liege, Belgium

[19] Grand Hop Charleroi, Charleroi, Belgium

[20] AZ Delta, Roeselare, Belgium

[21] JACIE Comm, Belgian Hematol Soc, Brussels, Belgium

来源：

BONE MARROW TRANSPLANTATION | 2019年 / 54卷 / 09期

关键词：

BONE-MARROW-TRANSPLANTATION; QUALITY MANAGEMENT-SYSTEM; EUROPEAN-SOCIETY; BLOOD; LEUKEMIA; ECONOMICS; MODELS; CARE; AGE;

D O I：

10.1038/s41409-019-0458-8

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

While performance since the introduction of the JACIE quality management system has been shown to be improved for allogeneic hematopoietic stem cell transplants (HSCT), impact on autologous-HSCT remains unclear in Europe. Our study on 2697 autologous-HSCT performed in adults in 17 Belgian centres (2007-2013) aims at comparing the adjusted 1 and 3-yr survival between the different centres & investigating the impact of 3 centre-related factors on performance (time between JACIE accreditation achievement by the centre and the considered transplant, centre activity volume and type of HSCT performed by centres: exclusively autologous vs both autologous & allogeneic). We showed a relatively homogeneous performance between Belgian centres before national completeness of JACIE implementation. The 3 centre-related factors had a significant impact on the 1-yr survival, while activity volume and type of HSCT impacted the 3-yr survival of autologous-HSCT patients in univariable analyses. Only activity volume (impact on 1-yr survival only) and type of HSCT (impact on 1 and 3-yr survivals) remained significant in multivariable analysis. This is explained by the strong relationship between these 3 variables. An extended transplantation experience, i.e., performing both auto & allo-HSCT, appears to be a newly informative quality indicator potentially conveying a multitude of underlying complex factors.

引用

页码：1434 / 1442

页数：9

共 37 条

[21] What is quality in a transplant program?
LeMaistre, CF
Loberiza, FR
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (04) : 241 - 246
[22] Vaccination of hematopoietic cell transplant recipients
Ljungman, P.
Cordonnier, C.
Einsele, H.
Englund, J.
Machado, C. M.
Storek, J.
Small, T.
[J]. BONE MARROW TRANSPLANTATION, 2009, 44 (08) : 521 - 526
[23] Transplant center characteristics and clinical outcomes after hematopoietic stem cell transplantation: what do we know
Loberiza, FR
Serna, DS
Horowitz, MM
Rizzo, JD
[J]. BONE MARROW TRANSPLANTATION, 2003, 31 (06) : 417 - 421
[24] Analyzing center specific outcomes in hematopoietic cell transplantation
Logan, Brent R.
Nelson, Gene O.
Klein, John P.
[J]. LIFETIME DATA ANALYSIS, 2008, 14 (04) : 389 - 404
[25] Review of Multistate Models in Hematopoietic Cell Transplantation Studies
Logan, Brent R.
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (01) : S84 - S87
[26] Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation
Majhail, Navneet S.
Farnia, Stephanie H.
Carpenter, Paul A.
Champlin, Richard E.
Crawford, Stephen
Marks, David I.
Omel, James L.
Orchard, Paul J.
Palmer, Jeanne
Saber, Wael
Savani, Bipin N.
Veys, Paul A.
Bredeson, Christopher N.
Giralt, Sergio A.
LeMaistre, Charles F.
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (11) : 1863 - 1869
[27] Hospital capacity and post-transplant survival after allogeneic bone marrow transplantation: analysis of data from the Japan Society for Hematopoietic Cell Transplantation
Matsuo, K
Hamajima, N
Morishima, Y
Harada, M
[J]. BONE MARROW TRANSPLANTATION, 2000, 26 (10) : 1061 - 1067
[28] Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant
Miller, CB
Piantadosi, S
Vogelsang, GB
Marcellus, DC
Grochow, L
Kennedy, MJ
Jones, RJ
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (04) : 1327 - 1332
[29] Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report
Passweg, J. R.
Baldomero, H.
Bader, P.
Bonini, C.
Duarte, R. F.
Dufour, C.
Gennery, A.
Kroeger, N.
Kuball, J.
Lanza, F.
Montoto, S.
Nagler, A.
Snowden, J. A.
Styczynski, J.
Mohty, M.
[J]. BONE MARROW TRANSPLANTATION, 2017, 52 (06) : 811 - 817
[30] Peters WP, 2003, HOLLAND FREI CANC ME

← 1 2 3 4 →